Kris V. Kowdley
Cancer Research · 2004–2023
A researcher in the Science corpus: 18 papers; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Cancer Research — 47 citations into it
- Molecular Biology — 47 citations into it
Whom Kris V. Kowdley trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Kris V. Kowdley overall
Papers from Kris V. Kowdley's perspective
Ordered by how strongly the researchers Kris V. Kowdley trusts endorse each paper. Same corpus, a different order for every researcher.
- Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.
- Self-assembly of mesoscopically ordered chromatic polydiacetylene/silica nanocomposites (Nature)
- Identification of Virus-Encoded MicroRNAs (Science)
- Identification of microRNAs of the herpesvirus family (Nature Methods)
- Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs (Nature)
- miRBase: microRNA sequences, targets and gene nomenclature (Nucleic Acids Res.)
- Identification of tissue-specific microRNAs from mouse. (Current Biology)
- Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA (Nature)
- Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia (Proceedings of the National Academy of Sciences of the United States of America)
- Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA (Science)
Their papers
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023) — 2,276 citations
- A multi-society Delphi consensus statement on new fatty liver disease nomenclature. (2023) — 2,621 citations
- Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease (2021) — 821 citations
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. (2019) — 1,024 citations
- Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection (2017) — 625 citations
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. (2016) — 957 citations
- All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study (2015) — 758 citations
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. (2015) — 854 citations
- Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. (2014) — 979 citations
- Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. (2014) — 1,255 citations
- ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. (2014) — 898 citations
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial (2014) — 2,063 citations
- Sofosbuvir for previously untreated chronic hepatitis C infection. (2013) — 1,908 citations
- MicroRNAs in Common Human Diseases (2012) — 353 citations
- Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases (2011) — 767 citations
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (2010) — 3,032 citations
- Global Epidemiology of Hepatitis B Virus (2004) — 669 citations
- Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial (2004) — 714 citations